Overview

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

Status:
Terminated

Trial end date:
2007-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether avosentan (SPP301) is effective in decreasing morbidity and mortality in patients with diabetic nephropathy.

Phase:

Phase 3

Details

Lead Sponsor:

Speedel Pharma Ltd.

Treatments:

Endothelin Receptor Antagonists